Clinical trials: Acute Ischaemic Stroke
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Acute Ischemic Stroke
Flow Arrest Safety and Technical Success With Balloon Guide Catheters
The objective of this post-market registry is to assess technical efficacy and safety associated with the use of the BOSS Balloon Guide Catheter during neuro-vascular procedures while providing temporary arrest of blood flow.
- Trial name
- FAST-BGC (NCT04416659)
- Testing
- Neuro-vascular access
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Stroke
Electroencephalograph for Detection of Acute Ischemic Stroke
The purpose of this study is Collecting data for an Electroencephalograph based algorithm for detection of onset and deterioration of Acute Ischemic Stroke by Comparison to NIHSS.
- Trial name
- NCT01737723
- Testing
- Neurokeeper stroke detector
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Neurokeeper Technologies
Ischemic Stroke
Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke
The purpose of this study is to evaluate the safety and tolerability of SA4503 in patients recovering from a recent stroke. Secondary, to evaluate the efficacy of SA4503 compared to placebo.
- Trial name
- NCT00639249
- Testing
- SA4503 Low, SA4503 High
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- M's Science Corporation
Stroke
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
- Trial name
- NCT00272909
- Testing
- piclozotan low dose, piclozotan high dose
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 43 people
- Sponsor
- Daiichi Sankyo
Stroke, Acute
An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)
RGTA® (ReGeneraTing Agent) are synthetic polysaccharides mimicking extra-cellular matrix scaffold elements and protective agents called Heparan Sulphates (HSPGs). OTR4132-MD is provided as a sterile injectable medical device.
- Trial name
- MATRISS (NCT04083001)
- Testing
- OTR4132MD
- Where
- 3 sites in France
- Volunteers
- 19 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Ischemic Stroke
Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke
To determine if the Trevo Retriever is as good or better than the Merci Retriever in restoring blood flow to the brain of a patient experiencing an acute ischemic stroke in a large vessel.
- Trial name
- TREVO2 (NCT01270867)
- Testing
- Mechanical Thrombectomy
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Stryker Neurovascular
Acute Ischemic Stroke
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts.
- Trial name
- NCT05547438
- Testing
- NTS-104 TRIS
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroTrauma Sciences, LLC
Stroke
Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)
The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial.
- Trial name
- DEDAS (NCT00638248)
- Testing
- Desmoteplase
- Volunteers
- 38 people
- Sponsor
- PAION Deutschland GmbH
Acute Ischemic Stroke, Vessel Occlusion
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.
- Conditions
- Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic
- Trial name
- "RESTORE" (NCT04451525)
- Testing
- MicroVention Mechanical Thrombectomy Devices as first-line treatment
- Where
- 37 sites in United States
- Volunteers
- 710 people
- Sponsor
- Microvention-Terumo, Inc.
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)
The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
- Trial name
- NCT06707987
- Testing
- Non-immunogenic staphylokinase
- Where
- Russia
- Volunteers
- 23,250 people
- Sponsor
- Supergene, LLC
Stroke, Acute, Stroke, Ischemic
Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation…
- Conditions
- Stroke, Acute, Stroke, Ischemic, Infarction, Middle Cerebral Artery, Strokes Thrombotic
- Trial name
- MEDIS (NCT03098732)
- Testing
- Magnetically Enhanced Diffusion (MED)
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Pulse Therapeutics
Acute Ischemic Stroke
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic…
- Trial name
- RESET (NCT05188417)
- Testing
- Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution
- Where
- China
- Volunteers
- 266 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Stroke
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more…
- Trial name
- GMAIS (NCT01221246)
- Testing
- GM602
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Stroke, Cerebral Ischemia
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00300196
- Testing
- Ancrod (Viprinex)
- Where
- 94 sites in United States, Australia and 9 more
- Volunteers
- 311 people
- Sponsor
- Neurobiological Technologies
Acute Cerebral Ischemia
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.
- Trial name
- FRONTIER (NCT02315443)
- Testing
- Nerinetide (NA-1)
- Where
- 4 sites in Canada
- Volunteers
- 532 people
- Sponsor
- NoNO Inc.
Stroke, Acute Stroke
Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke
This is a prospective, multicenter, double-blind, randomized, placebo-controlled, Phase Ib/IIa clinical study to assess the administration of ApTOLL together with endovascular therapy in acute ischemic stroke patients who are…
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke
- Trial name
- NCT04734548
- Testing
- ApTOLL
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- aptaTargets S.L.
Acute Ischemic Stroke
Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy
Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke
- Trial name
- iNFLOW-5 (NCT07571954)
- Testing
- Thromboaspiration catheter
- Where
- 7 sites in France, Spain
- Volunteers
- 45 people
- Sponsor
- iVascular S.L.U.